Literature DB >> 34731366

Remyelination in PNS and CNS: current and upcoming cellular and molecular strategies to treat disabling neuropathies.

Sedigheh Momenzadeh1,2, Mohammad-Saeid Jami3,4,5.   

Abstract

Myelin is a lipid-rich nerve cover that consists of glial cell's plasmalemma layers and accelerates signal conduction. Axon-myelin contact is a source for many developmental and regenerative signals of myelination. Intra- or extracellular factors including both enhancers and inhibitors are other factors affecting the myelination process. Myelin damages are observed in several congenital and hereditary diseases, physicochemical conditions, infections, or traumatic insults, and remyelination is known as an intrinsic response to injuries. Here we discuss some molecular events and conditions involved in de- and remyelination and compare the phenomena of remyelination in CNS and PNS. We have explained applying some of these molecular events in myelin restoration. Finally, the current and upcoming treatment strategies for myelin restoration are explained in three groups of immunotherapy, endogenous regeneration enhancement, and cell therapy to give a better insight for finding the more effective rehabilitation strategies considering the underlying molecular events of a lesion formation and its current condition.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Cell therapy; Demyelination; Endogenous regeneration; Immunomodulation; Remyelination

Mesh:

Year:  2021        PMID: 34731366     DOI: 10.1007/s11033-021-06755-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  95 in total

Review 1.  Schwann cells and their precursors emerge as major regulators of nerve development.

Authors:  K R Jessen; R Mirsky
Journal:  Trends Neurosci       Date:  1999-09       Impact factor: 13.837

2.  Akt-mediated survival of oligodendrocytes induced by neuregulins.

Authors:  A I Flores; B S Mallon; T Matsui; W Ogawa; A Rosenzweig; T Okamoto; W B Macklin
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

Review 3.  Myelin-associated glycoprotein (MAG): past, present and beyond.

Authors:  Richard H Quarles
Journal:  J Neurochem       Date:  2007-01-04       Impact factor: 5.372

Review 4.  Axonal regulation of myelination by neuregulin 1.

Authors:  Klaus-Armin Nave; James L Salzer
Journal:  Curr Opin Neurobiol       Date:  2006-09-07       Impact factor: 6.627

5.  The regulation of Krox-20 expression reveals important steps in the control of peripheral glial cell development.

Authors:  P Murphy; P Topilko; S Schneider-Maunoury; T Seitanidou; A Baron-Van Evercooren; P Charnay
Journal:  Development       Date:  1996-09       Impact factor: 6.868

6.  Calcineurin/NFAT signaling is required for neuregulin-regulated Schwann cell differentiation.

Authors:  Shih-Chu Kao; Hai Wu; Jianming Xie; Ching-Pin Chang; Jeffrey A Ranish; Isabella A Graef; Gerald R Crabtree
Journal:  Science       Date:  2009-01-30       Impact factor: 47.728

Review 7.  The repair Schwann cell and its function in regenerating nerves.

Authors:  K R Jessen; R Mirsky
Journal:  J Physiol       Date:  2016-03-21       Impact factor: 5.182

8.  Peripheral myelin protein 22 alters membrane architecture.

Authors:  Kathleen F Mittendorf; Justin T Marinko; Cheri M Hampton; Zunlong Ke; Arina Hadziselimovic; Jonathan P Schlebach; Cheryl L Law; Jun Li; Elizabeth R Wright; Charles R Sanders; Melanie D Ohi
Journal:  Sci Adv       Date:  2017-07-05       Impact factor: 14.136

Review 9.  Endoplasmic Reticulum Protein Quality Control Failure in Myelin Disorders.

Authors:  Vera G Volpi; Thierry Touvier; Maurizio D'Antonio
Journal:  Front Mol Neurosci       Date:  2017-01-04       Impact factor: 5.639

10.  Proteome profile of peripheral myelin in healthy mice and in a neuropathy model.

Authors:  Sophie B Siems; Olaf Jahn; Maria A Eichel; Nirmal Kannaiyan; Lai Man N Wu; Diane L Sherman; Kathrin Kusch; Dörte Hesse; Ramona B Jung; Robert Fledrich; Michael W Sereda; Moritz J Rossner; Peter J Brophy; Hauke B Werner
Journal:  Elife       Date:  2020-03-04       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.